selectabio.com - RNAC Income before deduction of interest, taxes and amortization

Graphic logo of Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics (RNAC) minimizes capital expenditures by outsourcing production and testing to external partners. The EBITDA financial metric illustrates this approach, where the 0.00 mark records this indicator. Stability is ensured by the Descartes platform with its closed scientific cycle, while growth potential is bolstered by the expansion of mRNA technologies into untapped niches for treating autoimmune pathologies.

RNAC Cartesian Therapeutics, Inc. Operating profit EBITDA (11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for Cartesian Therapeutics, Inc. (RNAC)

- market value and analyst target forecast:
Market Price Selecta Biosciences Inc.|RNAC - Consensus Target
- issuer market value details:
Market Value Cartesian Therapeutics|RNAC - Enterprise Value
- book capitalization information:
Accounting Value per Share Cartesian Therapeutics|RNAC - Book Capitalization|Market-to-Book Ratio selectabio.com|RNAC - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Cartesian Therapeutics|RNAC - Long-Term Debt to Equity|Short-Term Debt to Equity Selecta Biosciences|RNAC - Company Total Debt|Debt to Net Assets Ratio Cartesian Therapeutics|RNAC - Company Long-Term Debts|Short-Term Indebtedness Cartesian Therapeutics|Immediate Liquidity selectabio.com
- earnings and multiples data:
RNAC - Company Net Income|Net Profit Forecast Cartesian Therapeutics|RNAC - P/E Multiple|Projected Price to Earnings Ratio selectabio.com|RNAC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Cartesian Therapeutics|RNAC - Operating profit before deduction of amortization|Earnings per share for the last four quarters Cartesian Therapeutics|RNAC - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months selectabio.com|RNAC - Earnings growth in current year|Expected net earnings per share growth next year Cartesian Therapeutics
Fundamental company valuation:Selecta Biosciences Inc.
Manufactured products of Selecta Biosciences

Cash flow control is critical for the biotech company Cartesian Therapeutics (RNAC), which is developing mRNA therapy and expanding its pipeline. This indicator captures daily operating profit before taxes, interest, and depreciation, demonstrating the business's actual ability to cover costs amid tight monetary policy. An analysis of total EBITDA allows investors to assess the capital's financial resilience to market shocks and demand.

Who Cartesian Therapeutics competes with

Legend Biotech Corp. (LEGN) - Profit before interest, taxes and amortization|SANA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AUTL (autolus.com)|ALLO: Operating profit EBITDA|Operating profit before deduction of amortization Cellectis|CRBU (Caribou Bio) - Operating profit EBITDA|Profit before interest, taxes and amortization Instil Bio Inc TIL|Profit before payment of interest, taxes and amortization Genenta Science S.p.A. (GNTA)|Profit before payment of interest, taxes and amortization IPSC (centurytx.com)|Profit before payment of interest, taxes and amortization Jasper Therapeutics, Inc. JSPR|Senti Bio - Profit before payment of interest, taxes and amortization|ADAP: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CERO (CERo Therapeutics)|TCRT: Operating profit EBITDA|Operating profit before depreciation charges Achilles Therapeutics plc ACHL|CRGX (CARGO Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Poseida Therapeutics Inc PSTX|Profit before payment of interest, taxes and amortization 2seventy Bio (TSVT)|Gracell - Operating profit before amortization